Key result
Rivaroxaban shows no benefit over aspirin for stroke or systemic embolism after successful AF ablation.
Why the study?
Does rivaroxaban reduce a composite of stroke or systemic embolism in patients after successful catheter ablation for AF compared to aspirin?
Does rivaroxaban reduce a composite of stroke or systemic embolism in patients after successful catheter ablation for AF compared to aspirin?
In patients with successful catheter ablation for AF, rivaroxaban did not show a significant reduction in stroke or systemic embolism compared to aspirin at 36 months.
Answers are grounded in this paper and cite their sources.
Supports aspirin over rivaroxaban after successful AF ablation; challenges routine long-term OAC in low-moderate risk patients.[[1]](https://www.the-hospitalist.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Dodd et al. (2026) studied this question. Rivaroxaban did not reduce the composite of stroke or systemic embolism compared to aspirin at 36 months in patients after successful catheter ablation for atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: